Enanta Pharmaceuticals | ENTA - Assets


Enanta Pharmaceuticals reported $329.5M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Anika Therapeutics USD 179.39M 10.88M Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Immunic USD 189.74M 165.69M Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
J&J USD 201.06B 167M Jun/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Ligand Pharmaceuticals USD 1.53B 28.53M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Novavax USD 1.04B 133.35M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026